WO2023006029A1 - 帕唑帕尼口服药物组合物、其制备方法及应用 - Google Patents

帕唑帕尼口服药物组合物、其制备方法及应用 Download PDF

Info

Publication number
WO2023006029A1
WO2023006029A1 PCT/CN2022/108602 CN2022108602W WO2023006029A1 WO 2023006029 A1 WO2023006029 A1 WO 2023006029A1 CN 2022108602 W CN2022108602 W CN 2022108602W WO 2023006029 A1 WO2023006029 A1 WO 2023006029A1
Authority
WO
WIPO (PCT)
Prior art keywords
pazopanib
pharmaceutical composition
water
glycerin
ethanol
Prior art date
Application number
PCT/CN2022/108602
Other languages
English (en)
French (fr)
Inventor
郭桢
王璇
卢鹏程
付俊
王婷婷
应述欢
Original Assignee
上海博志研新药物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海博志研新药物技术有限公司 filed Critical 上海博志研新药物技术有限公司
Publication of WO2023006029A1 publication Critical patent/WO2023006029A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the invention relates to a pazopanib oral pharmaceutical composition, its preparation method and application.
  • Renal cell carcinoma is one of the most common tumors of the urinary system, accounting for 2% of adult malignant tumors. In China, the incidence of renal cell carcinoma ranks second among urological tumors, second only to bladder cancer. With the continuous advancement of diagnostic techniques, patients with renal cell carcinoma have been treated earlier, and the overall 5-year survival rate of renal cell carcinoma has reached 74%, but only 12% for patients with advanced metastasis.
  • VEGF Vascular Endothelial Growth Factor, vascular endothelial growth factor
  • VEGF Vascular Endothelial Growth Factor, vascular endothelial growth factor
  • VEGF acts as a tumor A key pro-angiogenic growth factor in neovascularization, it binds to VEGF receptor tyrosine kinase specifically highly expressed on the surface of neovascular endothelial cells, and activates tyrosine kinase to exert biological functions. Therefore, tumor vessel-targeted therapy targeting VEGF receptor tyrosine kinase (referring to the use of VEGF receptor tyrosine kinase inhibitors) has become a new way of tumor treatment in recent years.
  • Pazopanib (5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide, Also known as pazopanib) is a new oral angiogenesis inhibitor developed by GlaxoSmithKline that can interfere with the formation of new blood vessels required for the survival and growth of stubborn tumors, targeting the vascular endothelial growth factor receptor ( VEGFR), which acts by inhibiting the formation of new blood vessels to the tumor blood supply. It is a multi-tumor drug that has shown positive results in large clinical trials involving patients with soft tissue sarcoma and renal cell carcinoma.
  • VEGFR vascular endothelial growth factor receptor
  • Pazopanib is a BCS class II drug, which is an insoluble and hyperosmolar drug. Low solubility limits its bioavailability. In order to make pazopanib dissolve quickly, improve bioavailability and reduce side effects, it is of great social and economic value to develop a pharmaceutical composition with immediate release.
  • the invention provides a pazopanib oral pharmaceutical composition, comprising: an active drug, a polymer carrier, an organic solvent and/or water; the active drug is 5-[[4-[ (2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide or its salts;
  • the oral pharmaceutical composition of pazopanib includes: an active drug, a polymer carrier, an organic solvent and water; the active drug is 5-[[4-[ (2,3-Dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide or its salt; the oral drug of pazopanib
  • the pH of the composition is 3.0-4.5;
  • the polymer carrier is selected from polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), poloxamer, polyethylene glycol vitamin E succinate (TPGS), polyethylene glycol 15-hydroxystearate, polyoxyethylene 40 hydrogenated castor oil, polyoxyl ester 35 hydrogenated castor oil, povidone, crospovidone, hypromellose ( One or more in HPMC), hydroxypropyl cellulose, polyvinyl alcohol, Tween 80, polyvinylpyrrolidone (PVP) and polyethylene glycol;
  • the polymer carrier is selected from Soluplus and PVP A combination, a combination of Soluplus and TPGS, a combination of TPGS and HPMC, or Soluplus.
  • the weight ratio of the active drug to the polymer carrier is 1:10-10:1, such as 3:10, 3:8, 3:5, 2:5, 10:1 , 2:1, 1:2, 5:16, 1:4 or 1:8.
  • the active drug is preferably 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]pyrimidin-2-yl]amino] -2-Methylbenzenesulfonamide hydrochloride (pazopanib hydrochloride).
  • the concentration of the active drug is 5-20 mg/ml, such as 6-15 mg/ml, as an example concentration of 7 mg/ml, 7.5 mg/ml, 8 mg/ml, 9 mg/ml, 10 mg/ml ml, 11mg/ml, 12mg/ml, 12.5mg/ml, 13mg/ml, 14mg/ml.
  • the organic solvent is selected from one or more of ethanol, propylene glycol, glycerin, polyethylene glycol-300, polyethylene glycol-400 and polyethylene glycol-600; as an example, The organic solvent is selected from a combination of ethanol and glycerin, or a combination of ethanol, propylene glycol and glycerin.
  • the volume ratio of the organic solvent to the pazopanib pharmaceutical composition is 0.3 to 0.9, and the volume ratio refers to the volume of the organic solvent to the pazopanib pharmaceutical composition.
  • the ratio of the total volumes; as an example, the volume ratios are 0.3, 0.4, 0.5, 0.6, 0.7, 0.75, 0.8, 0.85, 0.9.
  • the volume ratio of the water to the pazopanib pharmaceutical composition is 0.1 to 0.7, and the volume ratio refers to the volume of water to the total volume of the pazopanib pharmaceutical composition. Ratio; as an example, the volume ratios are 0.1, 0.15, 0.2, 0.25, 0.3.
  • the oral pharmaceutical composition of pazopanib may further comprise a sweetener.
  • the sweetener is selected from one or more of aspartame, sucralose, fructose, sucrose, stevioside, glycyrrhizin, essence, fragrance, saccharin and sodium saccharin.
  • the mass ratio of the sweetener to the active drug is 1:5-5:1, such as 1:3, 1:4 or 2:1.
  • the oral pharmaceutical composition of pazopanib can be any of the following formulations:
  • Formula 1 7.5mg/ml pazopanib hydrochloride, 20mg/ml Soluplus, 5mg/ml PVP, 10% v/v ethanol, 20% v/v glycerin, 2.5mg/ml essence and 70% v/v water;
  • Formula 2 7.5mg/ml pazopanib hydrochloride, 10mg/ml Soluplus, 10mg/ml TPGS, 20% v/v ethanol, 5% v/v propylene glycol, 25% v/v glycerin, 2.5mg/ml essence and 50% v/v water;
  • Formula 3 7.5mg/ml pazopanib hydrochloride, 10mg/ml TPGS, 2.5mg/ml HPMC, 15% v/v ethanol, 15% v/v propylene glycol, 30% v/v glycerin, 2.5mg/ml essence and 40% v/v water;
  • Formula 4 10mg/ml pazopanib hydrochloride, 20mg/ml Soluplus, 5mg/ml PVP, 10% v/v ethanol, 60% v/v glycerin, 2.5mg/ml essence and 30% v/v water;
  • Formulation 5 10mg/ml pazopanib hydrochloride, 1mg/ml Soluplus, 20% v/v ethanol, 15% v/v propylene glycol, 40% v/v glycerin, 5mg/ml sweetocitrusin and 25% v/v water;
  • Formula 6 10mg/ml pazopanib hydrochloride, 5mg/ml Soluplus, 25% v/v ethanol, 50% v/v glycerin, 5mg/ml tangerine and 25% v/v water;
  • Formulation 7 10mg/ml Pazopanib Hydrochloride, 20mg/ml Soluplus, 20% v/v Ethanol, 15% v/v Propylene Glycol, 50% v/v Glycerin, 5mg/ml Rutrusin and 15% v/v water;
  • Formula 8 12.5mg/ml pazopanib hydrochloride, 40mg/ml Soluplus, 25% v/v ethanol, 60% v/v glycerin and 15% v/v water;
  • Formula 9 12.5mg/ml pazopanib hydrochloride, 50mg/ml Soluplus, 30% v/v ethanol, 10% v/v propylene glycol, 50% v/v glycerin and 10% v/v water;
  • Formulation 10 12.5 mg/ml pazopanib hydrochloride, 100 mg/ml Soluplus, 25% v/v ethanol, 15% v/v propylene glycol, 50% v/v glycerin and 10% v/v water.
  • the present invention also provides the preparation method of described pazopanib pharmaceutical composition, it comprises the following steps:
  • step (3) Mix the active drug with the solution B obtained in step (2), stir, and filter to obtain the pazopanib pharmaceutical composition.
  • the filtering is through a filter membrane, and the pore size of the filter membrane may be 0.01 ⁇ m ⁇ 1.0 ⁇ m, such as 0.45 ⁇ m.
  • the present invention also provides the application of the pazopanib oral pharmaceutical composition in the preparation of medicaments for treating and/or preventing tumors.
  • the tumor may be renal carcinoma or soft tissue sarcoma.
  • the present invention also provides the application of the pazopanib oral pharmaceutical composition in the preparation of pharmaceutical preparations.
  • the present invention also provides a pharmaceutical preparation, which contains the pazopanib oral pharmaceutical composition.
  • the pharmaceutical preparation may be an oral liquid.
  • the present invention also provides a method for treating and/or preventing tumors, which is to administer a therapeutically effective dose of pazopanib oral pharmaceutical composition or pharmaceutical preparation to the population in need.
  • the present invention provides a pazopanib oral pharmaceutical composition, its preparation method and application.
  • pazopanib is dispersed in the form of a solution, which can significantly improve the solubility and dissolution rate of pazopanib, significantly improve the bioavailability of the drug, and have high solubility, fast dissolution rate and high bioavailability.
  • it can improve patient compliance and solve difficult problems such as dysphagia in elderly patients.
  • step 3 Add the active drug to the solution B obtained in step 2, keep stirring, and filter through a 0.45 ⁇ m filter membrane to obtain the pazopanib pharmaceutical composition.
  • Pazopanib oral solution was prepared according to the pharmaceutical formulations listed in the above 10 examples, the pH value of the solution was adjusted to between 3.0-4.5, and it was packaged in a brown bottle.
  • the present invention prepares pazopanib oral solution according to embodiment 7, and has carried out influence factor high temperature (60 °C) test, high humidity (90%RH ⁇ 5%RH) test, illumination (total illuminance: 1.2 * 10 Lux. hr, total ultraviolet radiation 200W ⁇ hr/m 2 ) test and accelerated test (40°C/75%RH) results are shown in Table 3 below.
  • Pazopanib oral solution was prepared according to Example 7 as a test preparation, and commercially available pazopanib tablets (VOTRIENT, 200 mg/tablet) were used as a control preparation. According to the dose of 50mg/only/day and 100mg/only/day, the Beagle dog Pazopanib oral solution was orally administered respectively, and the Beagle dog VOTRIENT was orally administered according to the dosage of 200mg/only/day, and the comparison preparation and different doses of the test preparation were investigated in The pharmacokinetic properties in Beagle dogs, the pharmacokinetic results are shown in Table 4, and the PK curve is shown in Figure 1.
  • Example 7 can still significantly increase the exposure of API under the premise of 2 times and 4 times lower than the control dose, and the oral bioavailability is significantly improved.
  • the pazopanib oral solution of the present invention has good stability, can improve the mouthfeel of the preparation, and has significantly improved bioavailability compared with the control preparation.

Abstract

提供了帕唑帕尼口服药物组合物、其制备方法及应用。提供了一种帕唑帕尼口服药物组合物，其包括：活性药物、聚合物载体，有机溶剂和/或水；所述的活性药物为如式1所示的5-[[4-[（2,3-二甲基-2H-吲唑-6-基）甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺及其盐。帕唑帕尼以溶液形式分散，可显著改善帕唑帕尼的溶解度和溶出速度，显著提高药物的生物利用度，同时可提高患者顺应性、解决老年患者吞咽困难等难题。

Description

帕唑帕尼口服药物组合物、其制备方法及应用
本申请要求享有2021年7月30日向中国国家知识产权局提交的，专利申请号为202110871277.1，发明名称为“帕唑帕尼口服药物组合物、其制备方法及应用”的在先申请的优先权权益。所述在先申请的全文通过引用的方式结合于本申请中。
技术领域
本发明涉及一种帕唑帕尼口服药物组合物、其制备方法及应用。
背景技术
肾细胞癌简称肾癌，是泌尿系统最常见的肿瘤之一，发病率占成人恶性肿瘤的2％。在中国，肾细胞癌的发病率位居泌尿系肿瘤的第2位，仅次于膀胱癌。随着诊断技术的不断进步，肾癌患者得到了较早期的治疗，肾癌总体的5年生存率达到74％，但晚期转移者仅为12％。
VEGF(Vascular Endothelial Growth Factor，血管内皮细胞生长因子)是肿瘤血管生成过程中的一种血管生成因子，是内皮细胞分化的激素调节剂，实体瘤的发展与VEGF的表达呈密切相关，VEGF作为肿瘤新生血管形成中的关键性促血管生长因子，它与特异性高表达在新生血管内皮细胞表面的VEGF受体酪氨酸激酶结合，激活酪氨酸激酶从而发挥生物学功能。因而以VEGF受体酪氨酸激酶为靶点的肿瘤血管靶向性治疗(指使用VEGF受体酪氨酸激酶抑制剂)已成为近几年肿瘤治疗的新途径。
帕唑帕尼(5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺，亦称培唑帕尼)是由葛兰素史克公司研发的一种可干扰顽固肿 瘤存活和生长所需的新血管生成的新型口服血管生成抑制剂，靶向作用于血管内皮生长因子受体(VEGFR)，通过抑制对肿瘤供血的新血管生成而起作用。它是一种可以治疗多种肿瘤的药物，其在涉及软组织肉瘤和肾细胞癌患者的大规模临床试验中显示出了积极的结果。
帕唑帕尼为BCSⅡ类药物，属于难溶高渗性药物。溶解度低限制了其生物利用度，为了能使帕唑帕尼快速溶出、提高生物利用度，降低副作用，研究出一种具有速释性的药物组合物具有重要社会和经济价值。
目前，继续开发制备工艺简单、易于放大生产、且调整剂量更为方便、患者顺应性好的帕唑帕尼制剂。
发明内容
本发明提供了一种帕唑帕尼口服药物组合物，包括：活性药物、聚合物载体，有机溶剂和/或水；所述的活性药物为如式I所示的5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺或其盐；
Figure PCTCN2022108602-appb-000001
根据本发明的实施方案，所述帕唑帕尼口服药物组合物包括：活性药物、聚合物载体、有机溶剂和水；所述的活性药物为如式I所示的5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺或其盐；所述的帕唑帕尼口服药物组合物的pH为3.0～4.5；
Figure PCTCN2022108602-appb-000002
根据本发明的实施方案，所述的聚合物载体选自聚乙烯己内酰胺-聚醋 酸乙烯酯-聚乙二醇接枝共聚物(Soluplus)、泊洛沙姆、聚乙二醇维生素E琥珀酸酯(TPGS)、15-羟基硬脂酸聚乙二醇酯、聚氧乙烯40氢化蓖麻油、聚烃氧酯35氢化蓖麻油、聚维酮、交联聚维酮、羟丙甲基纤维素(HPMC)、羟丙基纤维素、聚乙烯醇、吐温80、聚乙烯吡咯烷酮(PVP)和聚乙二醇中的一种或多种；作为示例，所述聚合物载体选自Soluplus和PVP的组合、Soluplus和TPGS的组合、TPGS和HPMC的组合、或者Soluplus。
根据本发明的实施方案，所述活性药物与所述的聚合物载体的重量比为1:10～10:1，例如3:10、3:8、3:5、2:5、10:1、2:1、1:2、5:16、1:4或1:8。
根据本发明的实施方案，所述的活性药物优选为5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺盐酸盐(盐酸帕唑帕尼)。
根据本发明的实施方案，所述活性药物的浓度为5～20mg/ml，例如6～15mg/ml，作为示例浓度为7mg/ml、7.5mg/ml、8mg/ml、9mg/ml、10mg/ml、11mg/ml、12mg/ml、12.5mg/ml、13mg/ml、14mg/ml。
根据本发明的实施方案，所述有机溶剂选自乙醇、丙二醇、甘油、聚乙二醇-300、聚乙二醇-400和聚乙二醇-600中的一种或多种；作为示例，所述有机溶剂选自乙醇和甘油的组合，或者乙醇、丙二醇和甘油的组合。
根据本发明的实施方案，所述的有机溶剂与所述的帕唑帕尼药物组合物的体积比值为0.3～0.9，所述的体积比值是指有机溶剂的体积与帕唑帕尼药物组合物总体积的比值；作为示例，所述体积比值为0.3、0.4、0.5、0.6、0.7、0.75、0.8、0.85、0.9。
根据本发明的实施方案，所述水与所述的帕唑帕尼药物组合物的体积比值为0.1～0.7，所述的体积比值是指水的体积与帕唑帕尼药物组合物总体积的比值；作为示例，所述体积比值为0.1、0.15、0.2、0.25、0.3。
根据本发明的实施方案，所述的帕唑帕尼口服药物组合物还可以进一步包含甜味剂。
根据本发明的实施方案，所述甜味剂选自阿司帕坦、三氯蔗糖、果糖、蔗糖、甜菊苷、甘草甜素、香精、香料、糖精和糖精钠中的一种或多种。
根据本发明的实施方案，所述的甜味剂与所述的活性药物的质量比为1:5～5:1，例如1:3、1:4或2:1。
根据本发明示例性的实施方案，所述的帕唑帕尼口服药物组合物可以为以下任一配方：
配方1：7.5mg/ml盐酸帕唑帕尼、20mg/ml Soluplus、5mg/ml PVP、10％v/v乙醇、20％v/v甘油、2.5mg/ml香精和70％v/v水；
配方2：7.5mg/ml盐酸帕唑帕尼、10mg/ml Soluplus、10mg/ml TPGS、20％v/v乙醇、5％v/v丙二醇、25％v/v甘油、2.5mg/ml香精和50％v/v水；
配方3：7.5mg/ml盐酸帕唑帕尼、10mg/ml TPGS、2.5mg/ml HPMC、15％v/v乙醇、15％v/v丙二醇、30％v/v甘油、2.5mg/ml香精和40％v/v水；
配方4：10mg/ml盐酸帕唑帕尼、20mg/ml Soluplus、5mg/ml PVP、10％v/v乙醇、60％v/v甘油、2.5mg/ml香精和30％v/v水；
配方5：10mg/ml盐酸帕唑帕尼、1mg/ml Soluplus、20％v/v乙醇、15％v/v丙二醇、40％v/v甘油、5mg/ml甜橘苷和25％v/v水；
配方6：10mg/ml盐酸帕唑帕尼、5mg/ml Soluplus、25％v/v乙醇、50％v/v甘油、5mg/ml甜橘苷和25％v/v水；
配方7：10mg/ml盐酸帕唑帕尼、20mg/ml Soluplus、20％v/v乙醇、15％v/v丙二醇、50％v/v甘油、5mg/ml甜橘苷和15％v/v水；
配方8：12.5mg/ml盐酸帕唑帕尼、40mg/ml Soluplus、25％v/v乙醇、60％v/v甘油和15％v/v水；
配方9：12.5mg/ml盐酸帕唑帕尼、50mg/ml Soluplus、30％v/v乙醇、10％v/v丙二醇、50％v/v甘油和10％v/v水；
配方10：12.5mg/ml盐酸帕唑帕尼、100mg/ml Soluplus、25％v/v乙醇、 15％v/v丙二醇、50％v/v甘油和10％v/v水。
本发明还提供了所述的帕唑帕尼药物组合物的制备方法，其包括以下步骤：
(1)将聚合物载体和甜味剂与水形成溶液A；
(2)将有机溶剂与步骤(1)得到的溶液A混合，得到溶液B；
(3)将活性药物与步骤(2)得到的溶液B混合，搅拌，过滤，得到帕唑帕尼药物组合物。
根据本发明的实施方案，步骤3中，所述的过滤为经滤膜过滤，所述的滤膜的孔径可以为0.01μm～1.0μm，例如0.45μm。
本发明还提供了所述的帕唑帕尼口服药物组合物在制备治疗和/或预防肿瘤的药物中的应用。
根据本发明的实施方案，所述的肿瘤可以为肾癌或软组织肉瘤。
本发明还提供了所述的帕唑帕尼口服药物组合物在制备药物制剂中的应用。
本发明还提供一种药物制剂，含有所述帕唑帕尼口服药物组合物。
作为示例，所述的药物制剂可以为口服液。
本发明还提供了一种治疗和/或预防肿瘤的方法，其为给有需要的人群施用治疗有效量的帕唑帕尼口服药物组合物或药物制剂。
本发明的有益效果：
本发明为了克服现有技术中帕唑帕尼溶解度低、生物利用度低、副作用较大、患者顺应性差等缺陷而提供了一种帕唑帕尼口服药物组合物、其制备方法及应用。本发明组合物或制剂中帕唑帕尼以溶液形式分散，可显著改善帕唑帕尼的溶解度和溶出速度，显著提高药物的生物利用度，具有溶解度高、溶出速度快、生物利用度高的优点，同时可提高患者顺应性、解决老年患者 吞咽困难等难题。
附图说明
图1为比格犬口服给予实施例7受试及对照制剂后帕唑帕尼的平均药时曲线图(N＝3)。
具体实施方式
下文将结合具体实施例对本发明的技术方案做更进一步的详细说明。应当理解，下列实施例仅为示例性地说明和解释本发明，而不应被解释为对本发明保护范围的限制。凡基于本发明上述内容所实现的技术均涵盖在本发明旨在保护的范围内。
除非另有说明，以下实施例中使用的原料和试剂均为市售商品，或者可以通过已知方法制备。
实施例1-10
各实施例配方如表1-1、1-2所示。
表1-1
Figure PCTCN2022108602-appb-000003
Figure PCTCN2022108602-appb-000004
表1-2
Figure PCTCN2022108602-appb-000005
制备工艺：按照上述处方，
1.将聚合物载体和甜味剂溶于适量水中，搅拌均匀，得到澄清透明的溶液A；
2.将有机溶液加入步骤1得到的溶液A中，持续搅拌，得到澄清透明的溶液B；
3.将活性药物加入步骤2得到的溶液B中，持续搅拌，经0.45μm滤膜过滤，得到帕唑帕尼药物组合物。
稳定性考察
按照上述10个实施例中列举的药物制剂配方，制备成帕唑帕尼口服溶液，其溶液的pH值均调至3.0-4.5之间，采用棕色瓶包装。
考察项目：色泽、澄清度、外观性状、含量、降解产物，结果见表2。
表2 帕唑帕尼口服溶液考察结果
Figure PCTCN2022108602-appb-000006
本发明按实施例7制备帕唑帕尼口服溶液，并进行了影响因素高温(60℃)试验、高湿(90％RH±5％RH)试验、光照(总照度：1.2×10^6Lux·hr，总紫外辐度200W·hr/m 2)试验和加速试验(40℃/75％RH)结果见下表3。
表3 帕唑帕尼口服溶液稳定性考察结果
Figure PCTCN2022108602-appb-000007
Figure PCTCN2022108602-appb-000008
稳定性结果表明，实施例7的稳定性良好。
动物PK试验
按实施例7制备帕唑帕尼口服溶液作为受试制剂，以市售帕唑帕尼片(VOTRIENT，200mg/片)为对照制剂。按照50mg/只/天和100mg/只/天的剂量分别口服给予Beagle犬帕唑帕尼口服溶液，按照200mg/只/天的剂量口服给予Beagle犬VOTRIENT，考察对照制剂和不同剂量受试制剂在Beagle犬体内的药代动力学性质，药代学结果见表4，PK曲线见图1。
试验结果表明，实施例7在低于对照剂量2倍和4倍的前提下依旧能够显著提高API的暴露量，口服生物利用度明显提高。
表4 帕唑帕尼口服溶液和片剂在犬体内的药代动力学考察结果
Figure PCTCN2022108602-appb-000009
Figure PCTCN2022108602-appb-000010
以上说明，本发明帕唑帕尼口服溶液的稳定性良好，可改善制剂口感，与对照制剂相比生物利用度显著提高。
以上，对本发明的实施方式进行了说明。但是，本发明不限定于上述实施方式。凡在本发明的精神和原则之内，所做的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。

Claims (10)

  1. 一种帕唑帕尼口服药物组合物，其特征在于包括：活性药物、聚合物载体，有机溶剂和/或水；所述的活性药物为如式I所示的5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺或其盐；
    Figure PCTCN2022108602-appb-100001
  2. 如权利要求1所述的帕唑帕尼口服药物组合物，其特征在于：所述的帕唑帕尼口服药物组合物其pH为3.0～4.5；
    优选地，所述的聚合物载体包括聚乙烯己内酰胺-聚醋酸乙烯酯-聚乙二醇接枝共聚物、泊洛沙姆、聚乙二醇维生素E琥珀酸酯、15-羟基硬脂酸聚乙二醇酯、聚氧乙烯40氢化蓖麻油、聚烃氧酯35氢化蓖麻油、聚维酮、交联聚维酮、羟丙甲基纤维素、羟丙基纤维素、聚乙烯醇、吐温80、聚乙烯吡咯烷酮和聚乙二醇中的一种或多种。
  3. 如权利要求1或2所述的帕唑帕尼口服药物组合物，其特征在于：所述的活性药物为5-[[4-[(2,3-二甲基-2H-吲唑-6-基)甲氨基]嘧啶-2-基]氨基]-2-甲基苯磺酰胺盐酸盐；
    和/或，
    所述的活性药物与所述的聚合物载体的重量比为1:10～10:1；
    和/或，
    所述活性药物的浓度为5～20mg/ml。
  4. 如权利要求1～3任一项所述的帕唑帕尼口服药物组合物，其特征在于：所述有机溶剂包括乙醇、丙二醇、甘油和聚乙二醇-300、聚乙二醇-400和聚乙二醇-600中的一种或多种；
    和/或，
    所述的有机溶剂与所述的帕唑帕尼药物组合物的体积比值为0.3～0.9，所述的体积比值是指有机溶剂的体积与帕唑帕尼药物组合物总体积的比值。
  5. 如权利要求1～4任一项所述的帕唑帕尼口服药物组合物，其特征在于：所述的帕唑帕尼口服药物组合物进一步包含甜味剂；
    优选地所述甜味剂包括阿司帕坦、三氯蔗糖、果糖、蔗糖、甜菊苷、甘草甜素、香精、香料、糖精和糖精钠中的一种或多种；
    优选地，所述的甜味剂与所述的活性药物的质量比为1:5～5:1。
  6. 如权利要求1～5任一项所述的帕唑帕尼口服药物组合物，其特征在于：所述的帕唑帕尼口服药物组合物选自以下任一配方：
    配方1：7.5mg/ml盐酸帕唑帕尼、20mg/ml Soluplus、5mg/ml PVP、10％v/v乙醇、20％v/v甘油、2.5mg/ml香精和70％v/v水；
    配方2：7.5mg/ml盐酸帕唑帕尼、10mg/ml Soluplus、10mg/ml TPGS、20％v/v乙醇、5％v/v丙二醇、25％v/v甘油、2.5mg/ml香精和50％v/v水；
    配方3：7.5mg/ml盐酸帕唑帕尼、10mg/ml TPGS、2.5mg/ml HPMC、15％v/v乙醇、15％v/v丙二醇、30％v/v甘油、2.5mg/ml香精和40％v/v水；
    配方4：10mg/ml盐酸帕唑帕尼、20mg/ml Soluplus、5mg/ml PVP、10％v/v乙醇、60％v/v甘油、2.5mg/ml香精和30％v/v水；
    配方5：10mg/ml盐酸帕唑帕尼、1mg/ml Soluplus、20％v/v乙醇、15％v/v丙二醇、40％v/v甘油、5mg/ml甜橘苷和25％v/v水；
    配方6：10mg/ml盐酸帕唑帕尼、5mg/ml Soluplus、25％v/v乙醇、50％v/v甘油、5mg/ml甜橘苷和25％v/v水；
    配方7：10mg/ml盐酸帕唑帕尼、20mg/ml Soluplus、20％v/v乙醇、15％v/v丙二醇、50％v/v甘油、5mg/ml甜橘苷和15％v/v水；
    配方8：12.5mg/ml盐酸帕唑帕尼、40mg/ml Soluplus、25％v/v乙醇、 60％v/v甘油和15％v/v水；
    配方9：12.5mg/ml盐酸帕唑帕尼、50mg/ml Soluplus、30％v/v乙醇、10％v/v丙二醇、50％v/v甘油和10％v/v水；
    配方10：12.5mg/ml盐酸帕唑帕尼、100mg/ml Soluplus、25％v/v乙醇、15％v/v丙二醇、50％v/v甘油和10％v/v水。
  7. 如权利要求1～6任一项所述的帕唑帕尼口服药物组合物的制备方法，其特征在于包括以下步骤：
    (1)将聚合物载体和甜味剂与水形成溶液A；
    (2)将有机溶剂与步骤(1)得到的溶液A混合，得到溶液B；
    (3)将活性药物与步骤(2)得到的溶液B混合，搅拌，过滤，得到帕唑帕尼药物组合物。
  8. 如权利要求1～6任一项所述的帕唑帕尼口服药物组合物，在制备治疗和/或预防肿瘤的药物或药物制剂中的应用；
    优选地，所述的肿瘤为肾癌或软组织肉瘤。
  9. 一种药物制剂，其特征在于，含有权利要求1～6任一项所述的帕唑帕尼口服药物组合物。
  10. 如权利要求9所述的药物制剂，其特征在于：所述的药物制剂为口服液。
PCT/CN2022/108602 2021-07-30 2022-07-28 帕唑帕尼口服药物组合物、其制备方法及应用 WO2023006029A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110871277.1 2021-07-30
CN202110871277 2021-07-30

Publications (1)

Publication Number Publication Date
WO2023006029A1 true WO2023006029A1 (zh) 2023-02-02

Family

ID=85061091

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2022/108602 WO2023006029A1 (zh) 2021-07-30 2022-07-28 帕唑帕尼口服药物组合物、其制备方法及应用

Country Status (3)

Country Link
CN (1) CN115671110A (zh)
TW (1) TW202313043A (zh)
WO (1) WO2023006029A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132007A1 (en) * 1998-03-18 2002-09-19 University Technology Corporation Sustainded-release composition including amorphous polymer
CN1526387A (zh) * 2003-03-03 2004-09-08 浙江海正药业股份有限公司 紫杉醇囊泡注射剂及其制备方法
CN102083420A (zh) * 2008-06-30 2011-06-01 阿伯特有限及两合公司 包含聚合物载体组合物的剂型
CN105983098A (zh) * 2015-01-30 2016-10-05 湖北生物医药产业技术研究院有限公司 用于提高难溶性的抗肿瘤药物生物利用度的固体组合物及其制备方法
JP2020507556A (ja) * 2016-02-17 2020-03-12 トリアステック インコーポレイテッド 剤形およびそれらの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013208323B2 (en) * 2012-01-13 2017-07-06 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
CN104586770A (zh) * 2014-12-30 2015-05-06 山东博迈康药物研究有限公司 一种盐酸帕唑帕尼的热熔挤出制剂及其制备方法
EP3806858A4 (en) * 2018-06-15 2022-03-09 Handa Pharmaceuticals, Inc. SALTS OF KINASE INHIBITORS AND ASSOCIATED COMPOSITIONS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132007A1 (en) * 1998-03-18 2002-09-19 University Technology Corporation Sustainded-release composition including amorphous polymer
CN1526387A (zh) * 2003-03-03 2004-09-08 浙江海正药业股份有限公司 紫杉醇囊泡注射剂及其制备方法
CN102083420A (zh) * 2008-06-30 2011-06-01 阿伯特有限及两合公司 包含聚合物载体组合物的剂型
CN105983098A (zh) * 2015-01-30 2016-10-05 湖北生物医药产业技术研究院有限公司 用于提高难溶性的抗肿瘤药物生物利用度的固体组合物及其制备方法
JP2020507556A (ja) * 2016-02-17 2020-03-12 トリアステック インコーポレイテッド 剤形およびそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIU QIAO: "Multi-targeted Tyrosine Kinase Inhibitor-Pazopanib", CHINESE PHARMACEUTICAL JOURNAL, ZHONGGUO YAOXUEHUI ZHUBAN CHUBAN. ZHONGGUO-YAOXUE-ZAZHI BIANJI WEIYUANHUI, CN, vol. 14, 31 July 2011 (2011-07-31), CN , pages 1133 - 1135, XP093030193, ISSN: 1001-2494 *

Also Published As

Publication number Publication date
CN115671110A (zh) 2023-02-03
TW202313043A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
US11426391B2 (en) Pharmaceutical compositions
ES2731601T3 (es) Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
CN114599346A (zh) 一种含有醋酸阿比特龙的药物组合物及其制备方法和应用
US11957681B2 (en) Liquid dosage forms of Imatinib
TW201427659A (zh) 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物
AU2016263338B2 (en) SOMCL-9112 solid dispersion and preparation method thereof and SOMCL-9112 solid preparation containing SOMCL-9112 solid dispersion
RU2409363C9 (ru) Фармацевтические композиции для пероральной доставки дииндолилметана (dim) и способы применения этих композиций
WO2020119698A1 (zh) 一种维拉佐酮固体分散体及其制备方法
EP4032529A1 (en) Sorafenib pharmaceutical composition having high bioavailability and application
WO2023006029A1 (zh) 帕唑帕尼口服药物组合物、其制备方法及应用
CN115400099A (zh) 卡利拉嗪口溶膜组合物、其制备方法及应用
Wang et al. Evodiamine-loaded rhEGF-conjugated bovine serum albumin nanoparticles alleviate indomethacin-associated gastric mucosal injury in male SD rats
TWI835118B (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途
WO2023035200A1 (zh) 五氟利多在制备治疗子宫内膜癌的药物中的应用
WO2021175274A1 (zh) 奥拉帕尼溶出增强组合物
TW202245770A (zh) 布瑞哌唑口溶膜包合物、其製備方法及用途
CN117693333A (zh) 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用
WO2023093640A1 (zh) 一种达罗他胺药物组合物及其制备方法和用途
TW202245769A (zh) 布瑞哌唑口溶膜組合物、其製備方法及用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22848634

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022848634

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022848634

Country of ref document: EP

Effective date: 20240229